Memorializing Governor Kathy Hochul to proclaim September 2026, as Blood Cancer Awareness Month in the State of New York
This resolution memorializes Governor Kathy Hochul to proclaim September 2026 as Blood Cancer Awareness Month in New York State. It is a commemorative measure, not a regulatory bill, and is intended to align the state with National Blood Cancer Awareness Month. The resolution highlights blood cancers affecting the blood and lymphatic systems, including leukemia, chronic lymphocytic leukemia (CLL), lymphoma, Waldenstrom macroglobulinemia, multiple myeloma, and myelodysplastic syndromes.
The resolution emphasizes public education about symptoms, risk factors, treatment advances, and the importance of early recognition and medical evaluation. It notes that blood cancers remain a major health burden despite improved survival rates, and it points to ongoing research and emerging therapies such as CAR-T, bispecific antibodies, antibody-drug conjugates, and targeted precision medicines. The measure also underscores disparities in access to innovative treatments and specialized care, especially for CLL patients, and calls attention to the need for continued research and accessible care.
In terms of state law, the resolution does not amend the Public Health Law or create new legal obligations. Its practical effect is limited to a formal request that the Governor issue a proclamation and to the transmission of the resolution to the Governor and Blood Cancer United. The measure functions as a symbolic state recognition effort that may support awareness campaigns, advocacy, and public outreach by health organizations and affected communities.
The general sentiment around the resolution is strongly supportive and noncontroversial. The text frames blood cancer awareness as a public health priority and presents the observance as consistent with the Legislature’s tradition of recognizing health awareness months. Because the bill is a memorializing resolution, there is no recorded vote or committee debate in the provided materials, and no opposition is indicated.
No notable points of contention appear in the available record. The resolution does mention disparities in treatment access and the need for physician judgment in selecting therapies, but these are presented as reasons for awareness rather than as disputed policy issues. Overall, the measure is a ceremonial public-health resolution with broad supportive framing and no evident legislative controversy.
This resolution has no direct effect on New York statutes, regulations, or agency authority. Its legal impact is limited to expressing the Legislature’s intent that the Governor proclaim September 2026 as Blood Cancer Awareness Month and to formally transmitting that request. Any practical effect would be indirect, through increased public awareness, advocacy, and educational outreach rather than changes to state law or benefits.
The sentiment is uniformly positive and supportive. The resolution is framed as a customary and compassionate recognition of a serious disease affecting many New Yorkers and Americans, and it emphasizes awareness, research, and improved care. No votes, objections, or committee concerns are provided, suggesting the measure is ceremonial and noncontroversial.
No substantive contention is shown in the bill text or the available legislative history. The only policy-related themes are the need for better access to innovative blood cancer treatments, ongoing research, and physician-guided treatment decisions, but these are presented as factual findings rather than disputed issues. Because there are no recorded votes or committee transcripts, there is no evidence of opposition or disagreement among lawmakers.